Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tripelennamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.97 |
| ▸ | DRD1 | P21728 | 4/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.97 |
| ▸ | HTR2A | P28223 | 3/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.79 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tripelennamine SCHEMBL29363256 | 1.00 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Tripelennamine SCHEMBL17970 | 0.98 | CHRM2 (1.00) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Tripelennamine SCHEMBL29600775 | 0.98 | CHRM2 (1.00) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Tripelennamine SCHEMBL1652325 | 0.97 | CHRM2 (0.97) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Tripelennamine SCHEMBL15270438 | 0.93 | CHRM2 (0.89) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Chloropyramine SCHEMBL13723581 | 0.90 | CYP2D6 (0.95) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Tripelennamine SCHEMBL5432608 | 0.89 | CHRM2 (0.82) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Chloropyramine SCHEMBL34463428 | 0.88 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Hydrochloric Acid SCHEMBL29763485 | 0.88 | KDM4E (0.79) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 | |
| Chloropyramine SCHEMBL538104 | 0.88 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2MAPK1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2514 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036335-B2 | Adhesive containing microparticles | AVERY DENNISON CORPORATION (US) | 2024-07-16 | — | — | US | claimed |
| EP-3334820-B1 | INDUCED EXTENDED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USING | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) | 2024-05-15 | — | — | EP | claimed |
| US-20230310694-A1 | Adhesive Containing Microparticles | AVERY DENNISON CORPORATION | 2023-10-05 | — | — | US | claimed |
| US-11707549-B2 | Adhesive containing microparticles | AVERY DENNISON CORPORATION (US) | 2023-07-25 | — | — | US | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | claimed |
| US-20210046040-A1 | PAIN-RELIEVING TOPICAL COMPOSITIONS | INNOCAN PHARMA LTD. (IL) | 2021-02-18 | — | — | US | claimed |
| EP-3735225-A1 | PAIN-RELIEVING TOPICAL COMPOSITIONS | INNOCAN PHARMA LTD. (IL) | 2020-11-11 | — | — | EP | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| WO-2020012480-A1 | PAIN-RELIEVING TOPICAL COMPOSITIONS | INNOCAN PHARMA LTD. (IL) | 2020-01-16 | — | — | WO | claimed |
| WO-2019155389-A1 | AN AQUEOUS MUCOADHESIVE AND BIOADHESIVE COMPOSITION FOR THE TREATMENT | TARGET ONCOLOGY INC. (US) | 2019-08-15 | — | — | WO | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| US-5164406-A | Imidazole derivatives | BRISTOL-MYERS SQUIBB CO. (US) | 1992-11-17 | — | — | US | claimed |
| EP-0506207-A2 | Pharmaceutical vehicles for reducing transdermal flux | CHEMEX PHARMACEUTICALS, Inc. (US) | 1992-09-30 | — | — | EP | claimed |
| US-5053396-A | For treatment of symptoms associated with excessive alcohol intake, analgesic; nicotinamide or nicotinamide adenine dinucleotide | BLASS DAVID H (GB) | 1991-10-01 | — | — | US | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| US-4895727-A | Using water soluble zinc compound | CHEMEX PHARMACEUTICALS, INC. (US) | 1990-01-23 | — | — | US | claimed |
| EP-0349763-A1 | Compositions for enhancing transdermal penetration | Bristol-Myers Squibb Company (US) | 1990-01-10 | — | — | EP | claimed |
| US-4762704-A | Antiperspirant compositions, containing certain antihistamines and certain antihistamine enhancers | BRISTOL-MYERS COMPANY (US) | 1988-08-09 | — | — | US | claimed |
| US-4654209-A | NITROGLYCERINE PLUS STEROID, ANTIHISTAMINE, ANALGESIC, ANTIMICROBIAL | EUROCELTIQUE, S.A. (LU) | 1987-03-31 | — | — | US | claimed |
| US-4256743-A | PHENOTHIAZINES, ETHYLENEDIAMINES, INDENES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1981-03-17 | — | — | US | claimed |